ABU DHABI, UAE, May 11, 2026 /PRNewswire/ -- Binance has expanded access to Binance Institutional Loan, making the product available to all KYB-verified VIP clients, a significant broadening from the previous requirement of VIP 5 or above. The expansion is accompanied by a suite of product enhancements designed to give institutional borrowers greater capital efficiency, more predictable financing costs, and stronger incentives tied to trading activity.
The enhancements reflect growing institutional demand for more capital-efficient borrowing structures as participation in digital asset markets continues to deepen.
"Institutional clients need fast, flexible and capital-efficient access to liquidity," said Catherine Chen, Head of VIP & Institutional at Binance. "Binance Institutional Loan helps clients borrow against combined account equity without moving collateral between accounts. With eligibility now expanded to all KYB-verified VIP clients, more institutional participants can access this efficient financing solution."
Under the expansion, eligibility for Institutional Loan has been broadened from KYB-verified VIP 5+ users to all KYB-verified VIP users, substantially increasing product accessibility for more users.
Effective June 1, 2026, borrowers may also qualify for full monthly interest rebates through Binance's Interest Rebate Program by meeting performance targets tied to incremental trading volume share, Open Interest, or Net Asset Value. The program covers borrowing in USDT, USDC, BTC, and $U (United Stables), up to $10 million.
Binance has also raised the leverage cap for eligible clients from 4x to 5x, with the update applying automatically to both existing and newly onboarded users. In addition, Initial LTV has increased from 75% to 80%, and Transfer-Out LTV (excluding spot collateral) has increased from 75% to 83%, while Margin Call and Liquidation LTV thresholds remain unchanged at 85% and 90%, respectively.
The product now also supports fixed-rate term loans with 30-, 60-, and 90-day durations, giving institutional borrowers more flexibility and predictability in managing financing costs.
Availability: Binance Institutional Loan enables institutional clients to aggregate collateral across up to 10 sub-accounts to borrow USDC or USDT for Margin and Futures trading, with loan limits from $1 million to $10 million. KYB-verified clients at VIP 1 and above are eligible. To get started, institutional and sophisticated clients can contact their Binance VIP Account Manager or visit the FAQ for more details.
Disclaimer: The value of your investment may go down or up and you may not get back the amount invested. Institutional Loans carry substantial risk and amplify both losses and profits. All of your Institutional Lending Account balance may be liquidated, if prices move against you. Binance will not be liable for any losses you incur. Not financial advice. For more information, see our Terms of Use and Risk Warning.
About Binance
Binance is a leading global blockchain ecosystem behind the world's largest cryptocurrency exchange by trading volume and registered users. Binance is trusted by more than 310 million people in 100+ countries for its industry-leading security, transparency, trading engine speed, protections for investors, and unmatched portfolio of digital asset products and offerings from trading and finance to education, research, social good, payments, institutional services, and Web3 features. Binance is devoted to building an inclusive crypto ecosystem to increase the freedom of money and financial access for people around the world with crypto as the fundamental means. For more information, visit: https://www.binance.com.
About Binance VIP & Institutional
Binance VIP & Institutional empowers institutions and private wealth clients with robust asset management infrastructure, personalized VIP services and advanced end-to-end institutional trading tools on the world's largest cryptocurrency exchange by trading volume and registered users. With deep financial services experience in both traditional and crypto markets, its global team of trusted experts provides VIP & Institutional clients with the support they need to confidently capitalize on the industry's deepest liquidity and tightest markets.
For more information, visit: https://www.binanceinstitutional.com
Logo - https://mma.prnewswire.com/media/1773650/Binance_Logo_Yellow_4x_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/binance-expands-institutional-loan-access-to-all-kyb-verified-vip-clients-adds-interest-rebates-higher-leverage-and-fixed-rate-options-302768001.html
Apotheken in Deutschland erhalten deutlich mehr Handlungsspielraum: Der Bundesrat hat eine Reform der schwarz-roten Koalition passieren lassen, die die Rolle der Offizinen im Gesundheitswesen spürbar aufwertet. Ziel ist es, die wohnortnahe Versorgung zu stärken, Wartezeiten in Arztpraxen zu reduzieren und Prävention sowie Früherkennung auszubauen. Das Paket war zuvor bereits vom Bundestag beschlossen worden.
Kern der Reform ist ein erweitertes Leistungsangebot in Apotheken. Künftig sollen dort zusätzliche Vorsorge- und Früherkennungsuntersuchungen möglich sein, etwa zu Herz-Kreislauf-Erkrankungen, Diabetes oder Angeboten rund um das Rauchen. Apotheken können damit stärker als bisher in der Prävention ansetzen und Risiken identifizieren, bevor es zu manifesten Erkrankungen kommt.
Auch im Impfbereich werden die Kompetenzen ausgeweitet. Neben den bereits etablierten Grippe- und Corona-Impfungen dürfen Apotheken künftig alle Schutzimpfungen mit sogenannten Totimpfstoffen anbieten, darunter etwa Tetanus. Ergänzend werden Blutabnahmen erlaubt, etwa um Medikamentenwirkungen zu kontrollieren. Damit rücken Apotheken näher an klassische ärztliche Tätigkeitsfelder heran, ohne diese vollständig zu ersetzen.
Besonders sensibel ist die neue Möglichkeit, in eng begrenzten Fällen verschreibungspflichtige Medikamente ohne ärztliche Verordnung abzugeben. Erlaubt ist künftig die einmalige Ausgabe der kleinsten Packungsgröße auf Selbstzahlerbasis, wenn ein Arzneimittel seit längerem eingenommen wird und die Fortführung der Therapie keinen Aufschub erlaubt. Die Regelung soll Versorgungslücken schließen, etwa wenn ein Rezept nicht rechtzeitig vorliegt, und bleibt zugleich strikt begrenzt, um Missbrauch zu vermeiden.
